Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.59 GF Score: 50/100

RedHill Biopharma Ltd. - Special Call Transcript

Jun 15, 2020 / 04:40PM GMT
Release Date Price: €242 (-6.20%)
Unidentified Analyst

And we're going to move right on now to our next presenter. It is going to be RedHill Biopharma, and I'd like to introduce Alexandra Okmian and Gilead Raday, and I apologize for the mispronunciation of that, but you're -- both are welcome here, we're glad you're here.

RedHill Biopharma, you have our virtual stage now.

Gilead Raday
RedHill Biopharma Ltd. - COO

Thank you for joining RedHill's presentation at the MedInvest Virtual Infectious Diseases and Immunology Conference. I will focus today's presentation on RedHill's infectious diseases programs, including our rapidly advancing clinical stage COVID-19 therapeutic development program.

A standard disclaimer. The presentation contains forward-looking statements. In our presentation, no warranty is made to the accuracy or completeness of this presentation.

As for a few corporate highlights. RedHill is an emerging U.S. specialty company. We're primarily focused on U.S. commercialization and developments of drugs for GI diseases and anti-infectives. We have a strong U.S

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot